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esponsibility of Xi’Abstract An analytical method based on solid phase extraction was developed and validated for
analysis of adefovir in human plasma. Adefovir-d4 was used as an internal standard and Synergi MAX
RP80A (150 mm 4.6 mm, 4 mm) column provided the desired chromatographic separation of
compounds followed by detection with mass spectrometry. The method used simple isocratic chromato-
graphic condition and mass spectrometric detection in the positive ionization mode. The calibration curves
were linear over the range of 0.50–42.47 ng/mL with the lower limit of quantitation validated at 0.50 ng/mL.
Matrix effect was assessed by post-column infusion experiment to monitor phospholipids and post-
extraction addition experiment was performed. The degree of matrix effect for adefovir was determined as
7.5% and ion-enhancement in ﬁve different lots of human plasma was 7.1% and had no impact on study
samples analysis with 4.5 min run time. The intra- and inter-day precision values were within 7.7% and
7.8%, respectively, for adefovir at the lower limit of quantiﬁcation level. Validated bioanalytical method was
successfully applied to clinical sample analysis.
& 2015 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Adefovir, an acyclic phosphonate analog of deoxynucleoside mono-
phosphate (IUPAC name: {[2-(6-amino-9H-purin-9-yl) ethoxy]sity. Production and hosting by Else
2
194400.
npharma.com (D. Goswami).
an Jiaotong University.methyl} phosphonic acid, PMEA), is a broad spectrum antiviral
agent acting as a DNA polymerase inhibitor [1]. It has activity against
herpes virus (Epstein–Barr) and retroviruses including the human
immunodeﬁciency virus (HIV) [1]. Adefovir is largely used to treat
chronic hepatitis B in adults, though the drug is reported for poor oral
bioavailability [2]. The oral bioavailability of adefovir has been
substantially improved by using the bis-pivaloyloxymethyl ester of
adefovir (bis-POM PMEA, adefovir dipivoxil, Fig. 1) as a pro-drugvier B.V. All rights reserved.
LC–MS/MS method development for adefovir estimation 191with enhanced lipophilicity and achieving higher systemic adefovir
levels. Adefovir dipivoxil spontaneously hydrolyzes to mono-POM-
PMEA, which is rapidly converted into PMEA (adefovir) by enzyme.
Adefovir is an acyclic nucleoside analog of adenosine monopho-
sphate which is phosphorylated to the active metabolite adefovir
diphosphate by cellular kinases [2].
Although several methods have been reported to quantify
adefovir in human plasma [3–6] including serum [7], by employing
liquid chromatography–tandem mass spectrometry (LC–MS/MS),
analytical limitations could not be overcome. The published
methods demonstrated LC–MS/MS method for adefovir estimation
but lacked sensitivity and had lengthy run time [5,7]. Xie et al. [6]
developed an LC–MS/MS method for the determination of adefovir
with limit of quantitation 0.5 ng/mL but this method had matrix
related issue. The reported method failed to use labeled/deuterated
analog of adefovir for estimation from plasma to compensate
equivalent matrix effect with that of analyte. Vela et al. [8] had
developed an LC–MS/MS method using a very tedious and
complex ion-pairing technique for adefovir estimation. An interest-
ing LC–MS/MS method of adefovir had been reported with
emphasis on hydrophilic interaction but failed to achieve lower
limit of quantiﬁcation (LOQ) below 1.00 ng/mL [9]. Moreover,
Chen et al. [10] achieved sensitivity 0.25 ng/mL using protein
precipitation extraction method. But the method had lengthy
analysis run time (47 min) and also the method-related issue was
not addressed adequately.
Bioavailability/bioequivalence studies are frequently conducted
on healthy volunteers with adefovir dipivoxil 10 or 20 mg tablet,
marketed as Hespera (Gilead Sciences, Inc., Foster City, CA).
Regulatory guidance [11,12] suggests that LOQ should be
sufﬁcient to characterize pharmacokinetic parameters based on
expected peak plasma concentration (Cmax). European Medicine
Agency [12] suggests 5% of Cmax should be achieved to have
sufﬁcient sensitivity to capture proﬁle in elimination phase of a
drug. A monograph on adefovir states that the following oral
administration of a 10 mg single dose of Hespera in chronic
hepatitis B patients, the mean Cmax was 18.4 ng/mL with mean
elimination half-life of 7.48 h [13]. But, published literature
reﬂected high variation (14.9–24.7 ng/mL) in mean Cmax for
10 mg adefovir tablet, though administered to healthy volunteers
[9,10]. Such variation could be attributed to matrix effect or any
other aspects of method limitations. Therefore, it becomes
imperative to develop a precise, accurate, and high throughput
method for estimation of adefovir in human plasma. For conduct-
ing the bioequivalence study on adefovir (i.e. 10 mg Hespera
tablet), method sensitivity should be such that concentration proﬁle
up to 36 h (5 half lives) could be plotted. Though 1.0 ng/mLFig. 1 In-vivo hydrolysis of adLOQ could have sufﬁced [12] to characterize pharmacokinetic
parameter, we further decreased method sensitivity to 0.5 ng/mL.
In the present study, a systematic evaluation of matrix inter-
ference was investigated by using protein precipitation extraction
(PPE) followed by solid phase extraction (SPE) combination
technique to bring down matrix effect below 10% level effectively.
The unique method highlights adefovir stability as well as
selectivity in blank (untreated) plasma, hemolyzed and lipemic
plasma samples. The method had been successfully applied to
clinical sample analysis.2. Experimental
2.1. Chemicals and reagents
Working standards of adefovir (purity 99.35%) and adefovir-d4
(deuterium labeled adefovir; purity 98.0%) were procured from
Ranbaxy Research Laboratories Limited, India and Toronto
Research Chemicals, Canada, respectively. Ammonium acetate,
formic acid, liquor ammonia and methanol were purchased from
Qualigens Fine Chemicals (GSK Ltd., Mumbai, India). Oasiss
MAX (30 mg/1 cc) solid phase cartridges were purchased from
Waters Corporation (Milford Massachusetts, USA). Water was
puriﬁed using a Milli-Q device (Millipore, Bangalore, India).
Drug-free (blank) human plasma containing K3EDTA (ethylene-
diaminetetraacetic acid tripotassium salt), as anticoagulant, was
obtained from Yash Laboratories, New Delhi, India.
2.2. Preparation of calibration standards and quality control
samples
Adefovir, a water insoluble, polar drug [13], was found to be better
solubilized in acidiﬁed water (pH 1.2). Stock solutions of
adefovir and internal standard (ISTD) were prepared separately
by dissolving the accurately weighed compounds in acidiﬁed water
to obtain a ﬁnal concentration of approximately 1 mg/mL. Stock
solutions were stored at refrigerated temperature (1–10 1C). Two
separate stock solutions of adefovir were prepared for bulk spiking
of calibration standards (CS) and quality control (QC) samples.
Primary dilutions and working standard solutions were prepared
from stock solutions using methanol:water (50:50, v/v). These
working (standard) solutions were used to prepare the CS and QC
samples. Blank human K3EDTA plasma was screened prior to
spiking to ensure that it was free from endogenous interference at
retention times of adefovir and ISTD. Eight-point calibration
standards (CS) and QC samples were prepared by spiking theefovir dipivoxil to adefovir.
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Calibration standards samples were prepared at concentrations of
0.50, 1.27, 3.44, 6.88, 11.47, 19.11, 31.85 and 42.47 ng/mL. The
lowest limit of quantiﬁcation quality control (LOQQC), low
quality control (LQC), medium quality control (MQC) and high
quality control (HQC) samples were prepared at concentrations of
0.50, 1.41, 16.73 and 33.47 ng/mL, respectively. The (bulk) spiked
CS and QC samples were stored below 15 1C and protected
from light until analysis. The ISTD working solution (200.0 ng/
mL) was prepared in methanol:water (50:50, v/v).
2.3. Plasma sample preparation
500 mL of plasma sample was pipetted into polypropylene tubes
(12 mm  75 mm) and 50 mL of ISTD working solution
(200.0 ng/mL of ISTD) was added with the use of multistepper.
Samples were vortexed approximately for 30 s. Samples were
pretreated with 0.400 mL of 5% ammonia solution and vortexed
again (approximately for 30 s). The pretreated samples were
loaded onto the cartridge (Oasiss MAX, 30 mg/1 cc) and cen-
trifuged at 1500 rpm (or 453 g) for 1 min at 2–10 1C. The
cartridges were washed with 1 mL of 5% ammonia solution and
then 1 mL of methanol. Compounds were then eluted with 1 mL of
2% formic acid solution. The extracted samples were evaporated to
dryness at 20 psi and 50 1C under a stream of dry nitrogen using a
Zymark TurboVap LV evaporator (Caliper, Hopkinton, MA,
USA). Samples were reconstituted with 300 μL of reconstitution
solution (methanol:10 mM ammonium acetate: 70:30, v/v). The
reconstituted samples were transferred into autosampler glass
vials. 20 μL of sample was injected into the LC–MS/MS system
for analysis.
2.4. LC–MS/MS instrumentation and analytical conditions
The liquid chromatography separation was performed using a
Shimadzu scientiﬁc instruments (Shimadzu Corporation; Kyoto,
Japan) comprising two LC-20AD pumps, a cooling autosampler
(SIL 20AC), a column oven of temperature control (CTO-20AC)
and a CBM 20 A controller. Chromatographic separations were
achieved on Synergi MAX-RP 80A (150 mm 4.6 mm, 4 μm;
Phenomenex, Torrance, USA) column using a mobile phase
mixture of 10 mM ammonium acetate buffer (pH 8.7) and
methanol (75:25, v/v), at isocratic ﬂow rate of 0.6 mL/min. The
column and autosampler temperature were kept at 35 1C and
10 1C, respectively. An Applied Biosystems Sciex API 4000
(MDS-Sciexs, Concord, Canada) consists of an electrospray
ionization (ESI) interface, which was operated in positive ion
mode. Quantiﬁcation was carried out using multiple reaction
monitoring (MRM) mode of the transitions m/z 274.3-161.8
and 278.1-166.2 for adefovir and ISTD, respectively. Unit
resolution was applied to both Q1 and Q3. Dwell time was set
at 150 ms for adefovir and ISTD. Nitrogen was used as the
nebulizer, auxiliary, collision and curtain gas. The source para-
meters of the mass spectrometer were optimized and maintained as
follows: collision activated dissociation (CAD) gas, 6; curtain gas
(CUR), 40; gas 1 (nebulizer gas), 50; gas 2 (heater gas), 55; turbo
ion spray (IS) voltage, 5500 V; and source temperature, 650 1C.
Other optimized compound parameters for monitoring analyte were
set as follows: declustering potential (DP), 43 V; entrance potential
(EP), 8 V; collision energy (CE), 40 V; and collision cell exit
potential (CXP), 9 V.Calibration curves were constructed by calculating the analyte
to ISTD peak area ratio (y) against analyte concentrations (x). Data
acquisition and processing were performed using Analyst version
1.4.1 software (MDS Sciex, Toronto, Canada).2.5. Method validation
Method validation of adefovir in human plasma was carried out,
following US Food and Drug Administration guidelines and
Guidance from European Medicine Agency [11,12]. The method
was validated for selectivity, sensitivity, linearity, precision and
accuracy, recovery, matrix effect, re-injection reproducibility,
dilution integrity and stability of adefovir during both short-term
sample processing and long-term storage.2.5.1. Selectivity and signal-to-noise (S/N) ratio
The selectivity of the method towards endogenous plasma matrix
components, and concomitant medications was assessed in ten
batches (6 normal, 2 hemolyzed and 2 lipemic) of blank human
K3EDTA plasma. These samples were processed using the
proposed extraction protocol and analyzed with the set chromato-
graphic conditions at LOQ level. The peak area of the co-eluting
components or interferences in blank sample should be less than
20% and 5% from those of the analyte and ISTD, respectively.
The sensitivity was demonstrated by checking signal and noise in
spiked samples at the lowest quality control concentration. For
determination of signal-to-noise (S/N) ratio, four replicates of
LOQQC along with pooled blank matrix samples were processed
and analyzed. The S/N ratio of spiked samples was deemed
acceptable when
S=N ratio¼ Signal-to-noise ratio of LOQ
Mean of signal-to-noise ratio of blanks
452.5.2. Linearity and LOQ
Three calibration curves were used to demonstrate the linearity
of the method. The ratio of area responses for adefovir was used
for regression analysis. Each calibration curve was analyzed
individually by using least square weighted (1/x2) linear
regression (obtained by best ﬁt method). Back-calculations
were made from these curves to determine the concentration
of adefovir in each calibrator. A correlation coefﬁcient (r)
40.99 was desirable for all the calibration curves. The
sensitivity was demonstrated by checking signal and noise in
spiked samples at the lowest QC concentration. In addition, the
analyte peak at LOQQC concentration should be identiﬁable,
discrete and reproducible with accuracy within 720% and a
precision r20%.
2.5.3. Precision and accuracy
The intra- and inter-day precision and accuracy were performed for
adefovir in K3EDTA plasma. The intra-day accuracy and inter-day
accuracy were determined by replicate analysis of QC samples
(n¼6) at LOQQC, LQC, MQC and HQC. The precision of the
method was determined by calculating the percentage coefﬁcient of
variation (%CV) for each level. The deviation at each concentration
level from the nominal concentration was expected to be within
715.0%, excluding at LOQQC level (7 20%). Similarly, the mean
accuracy should not deviate by715.0%, excluding at LOQQC level
(720%).
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matrix effect
The relative recovery (RRE) for the analyte and ISTD at low,
middle and high QC concentration levels was determined by
measuring the mean peak area response of six replicates of
extracted quality control samples (spiked before extraction) against
the mean peak area response of post-extracted samples (spiked
after extraction) containing the analyte and ISTD at concentrations
equivalent to those obtained in the ﬁnal extracted concentration for
the analyte and ISTD in the QC samples.
RRE of adefovir and ISTD was estimated by using the
following equation:
% RRE ¼ Mean peak area of analyte in extracted samples
Mean peak area of analyte in post extracted samples
 100
The absolute matrix effect (AME) was estimated by the
following equation:
% AME¼ Mean peak area of in post extracted samples
Mean peak area of analyte in neat solutions
 100
When, AME¼1 indicates no matrix effect, AMEo1 indicates
ion-suppression and AME41 indicates ion-enhancement. As
extraction protocol involves a terminal drying step, hence spiking
(addition of reference samples) was carried out in post-extracted
blank plasma sample to perform matrix factor. The concentration
of the analyte and ISTD was obtained in reference sample
representing the QC concentration (at LQC, MQC and HQC
levels). The control sample was reference solution prepared at an
appropriate concentration in reconstitution solution.
2.5.5. Re-injection reproducibility and dilution integrity
Re-injection reproducibility was performed by injecting QC
samples (at LQC, MQC and HQC levels) from an accepted
precision-accuracy batch. The calculated concentration of
re-injected QC samples was determined against the CS samples
from the same precision and accuracy batch. Percentage difference
between original and re-injected value was calculated by using
following equation:
% Difference¼
jOriginal concentrationRe-injected concentrationj
Original concentration
 100
The dilution integrity experiment was performed with an aim to
validate the dilution test to be carried out on higher analyte
concentrations above upper limit of quantiﬁcation (ULOQ), which
may be encountered during real subject sample analysis. Dilution
integrity test was performed by preparing samples at a concentra-
tion approximately two times the concentration of 90% ULOQ.
These samples were diluted to two and four times with blank
matrix so as to bring the concentration within calibration curve and
then analyzed against fresh CS samples. The acceptance criteria
for the diluted QC samples should be the same as those of QC
samples in precision and accuracy batch.
2.5.6. Stability
Stability experiments were carried out to examine the analyte
stability in stock solutions and in plasma samples under different
conditions. Stock solution stability at refrigerated temperature
(1–10 1C) was assessed by comparing the peak area response of
stability sample of the analyte and ISTD with the area response ofsample prepared from fresh stock solutions. The stock solution of
adefovir and ISTD was considered stable if the deviation from
nominal value was within 710.0%. The stability of adefovir in
matrix was examined at low and high QC levels by analyzing
four replicates of QC samples against freshly spiked CS samples.
The stability data from various exercises, e.g., autosampler
stability, bench-top stability in plasma, freeze/thaw stability and
long-term stability were evaluated as per regulatory guidelines
[12,13].
The percentage stability was calculated by using the formula:
%Stability¼ Mean concentration of stability samples
Mean concentration of freshly spiked samples
 100
The bench-top stability of spiked plasma samples stored at room
temperature was evaluated for 6.5 h. The autosampler stability
was determined by storing reconstituted QC samples for 49 h
under autosampler condition (at 10 1C) before being analyzed. The
freeze–thaw stability was conducted by comparing the stability
samples that had been frozen below 15 1C and thawed at room
temperature three times, with freshly spiked QC samples. Four
aliquots of each LQC and HQC concentration level were used for
the freeze–thaw stability evaluation. For long-term stability
evaluation, the concentrations obtained after 76 days were
compared with initial concentrations. All stability exercises were
performed against freshly spiked CS samples.
Human K3EDTA whole blood spiked with working solutions
(at LQC and HQC levels) was prepared and kept at bench at room
temperature (stability samples). After 2.0 h aqueous dilutions were
spiked in human K3EDTA whole blood (comparison samples).
After plasma was separated from blood sample, four aliquots of
each QC sample (stability as well as comparison samples) were
analyzed. The percentage stability of adefovir in human whole
blood was calculated by mean of area ratio of stability samples
against the comparison samples. The analyte was considered stable
if the stability was within 85–115%. The percentage stability was
calculated using the formula:
%Stability¼ Mean area ratio of stability samples
Mean area ratio of comparison samples
 100
3. Results and discussion
3.1. MS parameters optimization
Primary objective of method development was to achieve adequate
sensitivity, minimum overall analysis time (plasma processing and
chromatographic run) and the use of a small plasma volume for
processing, which is crucial for adefovir, especially for lower
dosage formulation. To develop a rapid and sensitive method, it
was equally necessary to optimize the chromatographic and mass
spectrometric conditions, as well as to have an efﬁcient extraction
procedure for adefovir. The present study was conducted using
ESI ionization source as it produced high intensity for the analyte
and ISTD and a good linearity in regression curves.
Three pKa values i.e., 2, 4 and 7 (ACD/Chem Sketch software,
Version 12.5) are noted for adefovir. The pKa 7 is due to –NH2
group presence in purine nucleus while 2 and 4 pKa values are
attributed to two –OH groups (Fig. 1). The amino group, attached
to purine nucleus, was easily ionized in positive ion mode. ESI
mass spectrum for adefovir and ISTD, in the positive mode, was
dominant with protonated (MþH)þ ions as both were easily
D. Goswami et al.194protonated. Addition of base further enhanced the intensity of
these ions to obtain protonated precursor ion peaks at m/z 274.3
and 278.1 for adefovir and ISTD, respectively.
The mass fragmentation pattern of adefovir revealed several peaks
of signiﬁcant intensity by varying collision energy from 5 to 55 V
(using nitrogen as CAD gas). The observed fragmentation for the
protonated precursor ion of adefovir was noted as m/z 274 Da. The
protonated precursor ion of adefovir was stable up to 15 V collision
energy, with negligible fragmentation. This could be due to its high
stability and possibly due to low molecular mass of nitrogen as CAD
gas. Further increase in collision energy (up to 25 V) formed the
fragment at m/z 256 Da, but poor relative peak intensity (21%) wasFig. 2 Chromatograms of (A) blank plasma spiked with IS sample [at
ofadefovir-d4], (C) LLOQ, (D) ULOQ and (E) real subject sample (17.51noted. Such effect is due to loss of water molecule followed by rapid
elimination of phosphono methoxy group to form ion at m/z 162 Da.
However, the ion at m/z 162 Da was further fragmented (employing
collision energy of 30–35 V) with the loss of propyl group at m/z
136 Da. Though the fragments at m/z 145 Da and 136 Da were noted
by setting collision energy at 50 V, their intensities did not reach even
20%. Therefore, dominant fragment ion m/z 162 Da was stabilized at
35–40 V (with relative intensity 100%). This formed the basis of our
product ion selection, m/z 162, for quantitation. The MRM state ﬁle
parameters (like nebulizer gas, CAD gas, ion spray voltage, and
temperature) were suitably optimized to obtain a consistent and
adequate response for the analyte. A dwell time set at 150 ms perRT of adefovir], (B) blank plasma spiked with ISTD sample [at RT
ng/mL, after 1.0 h of oral administration).
Table 1 Intra- and inter-day precision and accuracy data for the determination of adefovir.
Spiked concentration (ng/mL) Intra-day (n¼6) Inter-day (n¼18)
Mean (ng/mL) Accuracy (%) CV (%) Mean (ng/mL) Accuracy (%) CV (%)
0.50 0.52 103.6 7.7 0.52 102.5 7.8
1.41 1.36 96.6 6.6 1.35 96.4 5.9
16.73 15.83 94.6 5.1 15.95 95.3 4.5
33.47 31.47 94.0 5.4 31.93 95.4 4.8
Table 2 Relative recovery of adefovir.
Spiked concentration
(ng/mL)
Mean peak area of adefovir (n¼6) Relative recovery (%)
Extracted samples (%CV) Post-extracted samples (%CV)
1.41 15,269.5 (5.4) 27,310.9 (2.9) 55.9
16.73 171,253.2 (5.8) 306,481.1 (1.7) 55.9
33.47 323,398.3 (4.5) 614,823.3 (1.1) 52.6
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ISTD MRMs.3.2. Chromatographic conditions and sample preparation
Chromatographic analysis of adefovir and ISTD was carried out
under isocratic conditions to obtain adequate response, sharp
peak shape, and a shorter run time. The use of volatile buffers
like ammonium formate and ammonium acetate (in combination
of methanol–acetonitrile) for the separation of adefovir had
been evaluated also. It was observed that the pH of mobile
phase and selection of column were critical parameters. Chro-
matographic separation was tried using various combinations of
methanol–acetonitrile, acidic buffers and additives (like formic
acid, glacial acetic acid and liquor ammonia solution) on
different reversed phase columns with 5 μm particle size [viz.,
Xterra column (150 mm 4.6 mm), Chromolith RP-18
(100 mm 4.6 mm), Atlantis HILLIC (100 mm 4.6 mm),
Ascentis C8 (100 mm 4.6 mm), Zorbax SB C8 (100 mm 4.6
mm), and BDS Hypersil C18 (50 mm 4.6 mm)] to optimize
liquid chromatographic parameters. The analytes showed non-
linear behavior on Chromolith RP-18 column while HILLIC column
was marked unsuitable due to co-eluting matrix compounds
especially with hemolyzed plasma samples. The Synergi MAX-RP
80A (150 mm 4.6 mm; 4 mm) column with C12 bonded phase
was sterically less hindered than a C18 and was therefore tried. The
column is bound to extreme surface area (475 m2/g) silica 80A,
produced desired hydrophobic retention. The required selectivity as
well as sharper, symmetric peaks, for both adefovir and ISTD, was
noted and matrix interference for hemolyzed and lipemic plasma
samples was deemed negligible. The mobile phase consisting of
10 mM ammonium acetate buffer and methanol (75:25, v/v) with
pH approximately 8.770.1 was found most suitable for eluting the
analyte and ISTD from Synergi MAX-RP 80A column within run
time of 4.5 min.
Initially, the extraction of adefovir was carried out via protein
precipitation (with acetonitrile, methanol, and acetone) but highbackpressure with frequent clogging of the column was noted.
Liquid–liquid extraction technique was also evaluated to isolate
the drugs from plasma using diethyl ether, dichloromethane,
methyl tert-butyl ether, and isopropyl alcohol (alone and in
combination) as extracting solvents. However, the recovery was
inconsistent with signiﬁcant ion enhancement (greater than 40%
CV). Furthermore, optimization of solid phase extraction was
done employing Waters Oasiss HLB, Waters Oasiss MCX,
Waters Oasiss MAX and Phenomenex Strata cartridges. Finally
better retention was provided on the Waters Oasiss MAX as
compared to other cartridges. Using 5% ammonia liquor and
methanol during washing step imparted consistent recovery
with minimal matrix interference. Current regulatory agencies
support ISTD should preferably belong to the same class, with
the same physicochemical and spectral properties, to improve
the method precision, accuracy and linearity. Adefovir-d4, an
isotopic labeled compound of adefovir, was selected as an ISTD
due to similar structural and physicochemical properties with
those of adefovir. Moreover, there was no signiﬁcant effect of
ISTD on analyte recovery, sensitivity, ion enhancement or
matrix effect.3.3. Method validation parameters
3.3.1. Selectivity and signal-to-noise (S/N) ratio
Representative chromatograms obtained from blank plasma,
plasma spiked with LOQ, and real subject sample for adefovir
and ISTD are presented in Fig. 2. The mean interference observed
at the retention time of the analyte between 10 different lots of
human plasma including hemolyzed and lipemic plasma (contain-
ing K3EDTA as the anticoagulant) was calculated as 3.4% and
0.4% for adefovir and ISTD, respectively. Six replicates of
LOQ samples were prepared from the cleanest blank samples
and analyzed samples were deemed acceptable with CV o 4%.
We observed S/N ratio was 425 during method validation and
clinical sample analysis, which was within an acceptable limit
[11,12].
Table 3 Absolute matrix effect (ion-enhancement) of adefovir.
Sample type Plasma lot Peak area of adefovir at concentration (ng/mL)
1.41 16.73 33.47
Post-extracted samples (Single lot, n¼2) 1 43603 559685 1127406
1a 45554 534991 1038213
Mean 44579 547338 1082810
Post-extracted samples (Multiple lots, n¼10) 2 46868 571947 1026528
2a 44433 547465 1075295
3 45759 581697 1106885
3a 40987 526511 1110504
4 42161 542187 1103694
4a 44654 565754 1093344
5 49387 519280 1129593
5a 45735 557184 1096702
6 45429 551333 1112542
6a 48356 593051 1189767
Mean 45377 555641 1104485
Neat sample solution (n¼4) 41432 523511 1051140
41392 523967 1027334
42963 509139 1027415
44207 522643 1004153
Mean 42499 519815 1027511
% Ion-enhancement in single plasma lot 4.9 5.3 5.4
% Ion-enhancement in ﬁve plasma lots 6.8 6.9 7.5
aDuplicate.
Table 4 Relative matrix effect of adefovir.
Plasma lot Calculated concentration (ng/mL)
LQC HQC
1 1.31 33.41
1a 1.34 33.20
2 1.36 32.81
2a 1.33 33.02
3 1.37 31.82
3a 1.40 32.63
4 1.38 32.11
4a 1.39 33.13
5 1.34 32.66
5a 1.42 33.41
6 1.44 32.93
6a 1.37 33.30
Mean 1.37 32.87
Spiked concentration (ng/mL) 1.41 33.47
Accuracy (%) 97.6 98.2
CV (%) 2.8 1.5
aDuplicate.
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The linearity of adefovir was determined by weighted least square
regression analysis of standard plot that consisted of eight point
standard curve. The calibration was linear from 0.50 to 42.47 ng/mL
for adefovir. Best-ﬁt calibration curves of chromatographic response
versus concentrations were determined by weighted least square
regression analysis with weighting factor of 1/concentration2. The
correlation coefﬁcient (r2) was consistently greater than 0.9997 duringthe course of validation for adefovir. Accuracy ranged from 99.2% to
103.8%, 94.0% to 103.6% and 95.3% to 102.5% for within batch,
intra- and inter-day, respectively. These were within the acceptance
criteria of 715% of the nominal value at low, middle and high QC
levels and within 720% of the nominal concentration at LOQQC
concentration. Precision ranged from 0.9% to 5.9%, 5.1% to 7.7% and
4.5% to 7.8% for within batch, intra-day and inter-day, respectively.
Precisions (%CV) were within the acceptance criteria of r15% at
Table 5 Stability of adefovir (n¼4).
Storage conditions Spiked concentration (ng/mL) Mean (ng/mL) Nominal (%) CV (%)
Bench-top stability (at room temp. for about 6.5 h) 1.41 1.38 98.3 1.5
33.47 33.25 99.3 0.7
Freeze–thaw stability (three cycles) 1.41 1.42 100.8 2.8
33.47 33.32 99.6 1.4
In-injector stability (49 h) 1.41 1.42 100.9 2.1
33.47 33.12 98.9 1.2
Long term stability (below 15 1C for 76 days) 1.41 1.45 103.4 2.1
33.47 34.78 103.9 2.7
Table 6 Whole blood stability.
Spiked concentration (ng/mL) Mean peak area of adefovir (n¼4) Stability
(%)
Stability samples (%CV) Comparison samples (%CV)
1.41 14,901 (6.3) 13,991 (1.8) 106.5
33.47 344,122 (3.5) 344,646 (4.4) 99.8
Fig. 3 The linear plasma mean concentration versus time proﬁle.
LC–MS/MS method development for adefovir estimation 197low, middle and high QC concentrations and r20% at LOQQC
concentration. Intra- and inter-day precision and accuracy are presented
in Table 1.3.3.3. Relative recovery, absolute matrix effect and relative
matrix effect
The relative recoveries of adefovir at LQC, MQC and HQC levels
were 55.9%, 55.9% and 52.6%, respectively. The precision of
relative recovery across the low, middle and high QC levels was
3.5% and the results are shown in Table 2.
The assessment of matrix effect constitutes an important and
integral part of validation for quantitative LC–MS/MS for support-
ing pharmacokinetic studies. The results of absolute matrix effect
are acceptable (CV less than 6% at all QC levels). The ion
enhancement was 4.9–5.4% (for single lot) and 6.8–7.5% (for ﬁvedifferent lots) of human plasma, which is demonstrated in Table 3.
The acceptable results of relative matrix effect are presented in
Table 4. Also, a matrix-effect experiment by the post-infusion
method was conducted during method development to check ion
suppression or enhancement at adefovir and ISTD retention times.
It was conﬁrmed that there was no signiﬁcant ion enhancement at
retention times of adefovir and ISTD.3.3.4. Re-injection reproducibility and dilution integrity
Re-injection reproducibility exercise was performed to check
whether the instrument performance remains unchanged after
hardware deactivation because of any instrument failure during
real subject sample analysis. Percentage difference for all re-
injected QC samples (at LQC, MQC and HQC levels) was less
than 2.9 and deemed acceptable. The result of dilution integrity
was deemed acceptable for 2 times and 4 times dilutions.3.3.5. Stability
Stock solution stability was performed to check stability of adefovir and
ISTD in stock solutions prepared in acidiﬁed water (pH 1.2) and
stored at 1–10 1C in a refrigerator. The freshly prepared stock solutions
were compared with stock solutions prepared before 16 days. The
percentage changes for adefovir and ISTD were 0.6 and 2.2,
respectively, which indicate that stock solutions were stable for at least
15 days. Bench-top stability and autosampler stability for adefovir were
investigated at LQC and HQC levels. The results revealed that adefovir
was stable in plasma for at least 6.5 h at room temperature and 49 h
in an autosampler temperature (10 1C). It was conﬁrmed that repeated
freezing and thawing (three cycles) of plasma samples, spiked with
adefovir at LQC and HQC levels, did not affect their stability.
The long-term stability results also indicated that adefovir was
stable in matrix up to 76 days, stored below 15 1C. The results
obtained from all these stability studies are shown in Table 5.
Whole blood stability data were found acceptable and are presented
in Table 6.
Table 7 Pharmacokinetic parameters (mean7SD) of adefovir after the administration of an oral dose of 10 mg test and reference
adefovir formulations to healthy Indian male volunteers.
Parameters Test Reference
Tmax (h) 1.0070.50 1.0070.50
Cmax (ng/mL) 17.9173.43 19.0373.47
AUC0-t (ng h/mL) 205.74738.80 209.49744.51
AUC0-1 (ng h/mL) 213.64739.24 218.58744.86
t1/2 (h) 7.5671.27 7.5071.51
Table 8 Representative incurred sample re-analysis data with I as the ﬁrst period and II as the second period.
Subject no. Period Time point (h) Calculated concentration (ng/mL) Difference (%)
Original Re-analyzed
2 II 0.750 20.03 19.37 3.4
II 24.000 1.79 1.84 3.1
5 I 2.000 16.48 16.08 2.5
I 4.333 14.21 13.76 3.2
I 24.000 1.65 1.68 1.9
9 II 1.667 22.85 22.97 0.6
II 4.333 17.51 17.15 2.1
II 24.000 1.84 1.74 5.4
20 I 1.000 18.66 17.91 4.1
I 4.000 15.56 14.99 3.7
I 24.000 2.15 2.08 3.0
30 I 0.750 19.71 18.58 5.9
II 24.000 2.26 2.13 6.2
36 I 1.000 17.49 16.24 7.4
I 24.000 1.69 1.64 2.6
D. Goswami et al.1983.4. Method application
An open label, balanced, randomized, two-treatment, two-period,
two-sequence, single-dose, crossover design was used for the
assessment of pharmacokinetics and bioequivalence. Thirty-six
healthy adult male volunteers who gave written informed consent
took part in this study. The study was approved by Ethics
Committee of Institutional Review Board at Majeedia Hospital
(New Delhi, India). After an overnight fast of at least 10 h, all
subjects were given a single oral dose of 10 mg adefovir dipivoxil
immediate release tablet during each period of the study. Blood
samples were collected before (pre-dose) and at 0.167, 0.333,
0.500, 0.750, 1.000, 1.333, 1.667, 2.000, 2.333, 2.667, 3.000,
3.333, 3.667, 4.000, 4.333, 4.667, 5.000, 5.500, 6.000, 8.000,
12.000, 16.000, 24.000, 36.000 and 48.000 h post-dose in each
period. After separation of plasma from the blood by centrifuga-
tion, plasma samples were stored frozen below 15 1C until
analysis.
The plasma mean concentration time proﬁle of adefovir
is depicted in Fig. 3. The estimated pharmacokinetic parameters
derived from the plasma concentration proﬁles are summarized in
Table 7. Bioequivalence was established for Ranbaxy test drug
and innovator Hespra 10 mg adefovir dipivoxil immediate release
tablet. Further mean plasma concentration at 36 h sampling time
point was computed as 0.73 ng/mL. The present method LOQ of
0.5 ng/mL was justiﬁed since concentration-proﬁle till 5 half
lives of drug (10 mg adefovir tablet) was captured with 0.5 ng/
mL sensitivity.The results of incurred sample re-analysis (ISR) showed that
98.4% sampling point concentrations for adefovir were within
720% of original concentration value.
The %difference from the original analysis was calculated as
%Difference¼ Re-analyzed concentrationOriginal concentration
Mean concentration
 100
These results additionally supported our improved method
techniques and reproducibility of data for subject sample analysis
as well. Representative ISR data are further presented in Table 8.4. Conclusion
In summary, a rapid, speciﬁc, reproducible and high-throughput LC–
MS/MS method to quantify adefovir using adefovir-d4 as an internal
standard was developed and validated. The reported literature failed
to highlight a systematic procedure to control ion-enhancement
which is the intrinsic property of typical anti-viral drug adefovir. Our
method is highly selective and addresses the short-comings of
previous reported methods. The selectivity of method in hemolyzed
and lipemic plasma and stability of adefovir in blood are unique
features of the method. Overall the developed method presented
adequate sensitivity, excellent selectivity, controlled ion enhance-
ment and desired reproducibility for the quantiﬁcation of adefovir in
human plasma. The other major advantage of this validated method
is the shorter runtime of 4.5 min, allowing the quantitation of over
300 samples per day. Bioequivalence was established with Hepseras
LC–MS/MS method development for adefovir estimation 19910 mg adefovir tablets and pharmacokinetic parameters were similar
to that of the monograph on innovator [13] based on our improved
method. This method has been extensively validated like our
previous method validation reported [14,15], catering to the require-
ment of global regulatory agencies like USFDA and EMA. More-
over, the ISR at the end of the study further added strength to our
current method. All these advantages would make it efﬁcient for
routine therapeutic drug monitoring as well as for the analysis of
large number of plasma samples obtained from exploratory pharma-
cokinetic studies.
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